Protalix Biotherapeutics Inc (NYSE MKT:PLX) — Market Cap & Net Worth
Market Cap & Net Worth: Protalix Biotherapeutics Inc (PLX)
Protalix Biotherapeutics Inc (NYSE MKT:PLX) has a market capitalization of $156.31 Million ($156.31 Million) as of September 17, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #17562 globally and #4155 in its home market, demonstrating a 5.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Protalix Biotherapeutics Inc's stock price $2.10 by its total outstanding shares 80571642 (80.57 Million). Also see Protalix Biotherapeutics Inc asset portfolio for a full breakdown of the balance sheet.
Protalix Biotherapeutics Inc Market Cap History: 2015 to 2026
Protalix Biotherapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $821.83 Million to $169.20 Million (-13.53% CAGR). Also see PLX cash flow metrics for how efficiently the company converts equity into cash flow.
Protalix Biotherapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Protalix Biotherapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check PLX live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.75x
Protalix Biotherapeutics Inc's market cap is 2.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $358.54 Million | $9.20 Million | -$29.36 Million | 38.98x | N/A |
| 2017 | $532.74 Million | $21.08 Million | -$83.44 Million | 25.27x | N/A |
| 2018 | $250.58 Million | $34.24 Million | -$26.46 Million | 7.32x | N/A |
| 2019 | $264.27 Million | $54.69 Million | -$18.28 Million | 4.83x | N/A |
| 2020 | $292.48 Million | $62.90 Million | -$6.52 Million | 4.65x | N/A |
| 2021 | $67.01 Million | $38.35 Million | -$27.58 Million | 1.75x | N/A |
| 2022 | $110.38 Million | $47.64 Million | -$14.93 Million | 2.32x | N/A |
| 2023 | $143.42 Million | $65.49 Million | $8.31 Million | 2.19x | 17.25x |
| 2024 | $151.47 Million | $53.40 Million | $2.93 Million | 2.84x | 51.66x |
| 2025 | $145.03 Million | $52.74 Million | -$6.60 Million | 2.75x | N/A |
Competitor Companies of PLX by Market Capitalization
Companies near Protalix Biotherapeutics Inc in the global market cap rankings as of September 17, 2026. Review PLX goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Protalix Biotherapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Protalix Biotherapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Protalix Biotherapeutics Inc's market cap moved from $821.83 Million to $ 169.20 Million, with a yearly change of -13.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $169.20 Million | +16.67% |
| 2025 | $145.03 Million | -4.26% |
| 2024 | $151.47 Million | +5.62% |
| 2023 | $143.42 Million | +29.93% |
| 2022 | $110.38 Million | +64.72% |
| 2021 | $67.01 Million | -77.09% |
| 2020 | $292.48 Million | +10.67% |
| 2019 | $264.27 Million | +5.47% |
| 2018 | $250.58 Million | -52.96% |
| 2017 | $532.74 Million | +48.58% |
| 2016 | $358.54 Million | -56.37% |
| 2015 | $821.83 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Protalix Biotherapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $156.31 Million USD |
| MoneyControl | $156.31 Million USD |
| MarketWatch | $156.31 Million USD |
| marketcap.company | $156.31 Million USD |
| Reuters | $156.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also d… Read more